Observations from the OMERACT Drug Safety Summit, May 2008

Lee S. Simon; C. Vibeke Strand; Maarten Boers; Peter M. Brooks; David Henry; Peter S. Tugwell

doi:10.3899/jrheum.090590

Observations from the OMERACT Drug Safety Summit, May 2008

Lee S. Simon, C. Vibeke Strand, Maarten Boers, Peter M. Brooks, David Henry, Peter S. Tugwell

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology

Original language	English
Pages (from-to)	2110-2113
Number of pages	4
Journal	Journal of Rheumatology
Volume	36
Issue number	9
DOIs	https://doi.org/10.3899/jrheum.090590
Publication status	Published - Sept 2009
Externally published	Yes

Access to Document

10.3899/jrheum.090590

Cite this

@article{2588d24f3a9e474e921db290c7986b01,

title = "Observations from the OMERACT Drug Safety Summit, May 2008",

abstract = "Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology",

author = "Simon, {Lee S.} and Strand, {C. Vibeke} and Maarten Boers and Brooks, {Peter M.} and David Henry and Tugwell, {Peter S.}",

year = "2009",

month = sep,

doi = "10.3899/jrheum.090590",

language = "English",

volume = "36",

pages = "2110--2113",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "9",

}

TY - JOUR

T1 - Observations from the OMERACT Drug Safety Summit, May 2008

AU - Simon, Lee S.

AU - Strand, C. Vibeke

AU - Boers, Maarten

AU - Brooks, Peter M.

AU - Henry, David

AU - Tugwell, Peter S.

PY - 2009/9

Y1 - 2009/9

N2 - Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology

AB - Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology

UR - http://www.scopus.com/inward/record.url?scp=70349230070&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090590

DO - 10.3899/jrheum.090590

M3 - Article

C2 - 19738222

AN - SCOPUS:70349230070

SN - 0315-162X

VL - 36

SP - 2110

EP - 2113

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 9

ER -

Observations from the OMERACT Drug Safety Summit, May 2008

Abstract

Access to Document

Other files and links

Fingerprint

Cite this